Therapeutic effects of different doses of recombinant human prourokinase on STEMI patients undergo-ing PCI and its influence on peripheral blood CD62p and Adropin levels
10.3969/j.issn.1008-0074.2025.05.11
- VernacularTitle:不同剂量重组人尿激酶原对行PCI术的STEMI患者的疗效及对外周血CD62p、Adropin的影响
- Author:
Qiu-li CUI
1
;
Zan-ping LEI
1
;
Ming-zhen FAN
1
Author Information
1. 渭南市第二医院心血管内科,陕西渭南 714000
- Publication Type:Journal Article
- Keywords:
Myocardial infarction;
Angioplasty,balloon,coronary;
Recombinant human prourokinase
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2025;34(5):652-658
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate ⅰ)the therapeutic effects of different doses of recombinant human prourokinase(rh-proUK)on patients with ST segment elevation myocardial infarction(STEMI)undergoing percutaneous coronary inter-vention(PCI),and ⅱ)its impact on peripheral blood P-selectin(CD62p)and Adropin levels.Methods:This randomized control study enrolled 132 STEMI patients undergoing PCI in Weinan Second Hospital between June 2020 and June 2023.Patients were randomly divided into control group(n=44,routine medication),low dose group(n=44,10 mg rh-proUK therapy)and high dose group(n=44,20 mg rh-proUK therapy).Therapeutic effective rate,myocardial perfu-sion immediate after operation,cardiac function,peripheral blood CD62p and Adropin levels,incidence of major adverse cardiovascular events(MACE)within 1 month after operation were compared among three groups.Results:Compared to patients in control group,those in high dose group had significantly higher total effective rate(95.5％vs.54.6％),pro-portions of TIMI myocardial perfusion grade(TMPG)grade 3(86.4％vs.25.0％)and ST segment resolution above 30％(∑STR≥30％)(88.6％vs.59.1％),stroke volume(SV)[(76.81±24.47)ml vs.(61.89±14.84)ml]and cardiac output(CO)[(6.48±1.45)L/min vs.(5.48±1.98)L/min],and significantly lower corrected TIMI frame count(CT-FC)[(31.80±6.32)frames vs.(52.39±7.14)frames],CD62p[(70.52±9.54)％vs.(82.42±12.44)％],Adropin[(82.48±9.55)pg/ml vs.(94.48±10.53)pg/ml]and total incidence of MACE(9.1％vs.38.6％)(P＜0.05 or＜0.01).Compared to those in low dose group,patients in high dose group had significantly higher total effective rate,pro-portions of TMPG grade 3 and ∑STR≥30％,SV and CO,and significantly lower CTFC,CD62p,Adropin and total inci-dence of MACE(P＜0.05 or＜0.01).Conclusion:The therapeutic effect of 20 mg rh-proUK on STEMI patients under-going PCI is significantly better than that of 10 mg,which could improve cardiac function,reduce CD62p,Adropin levels,and incidence of major adverse cardiovascular events.
